In advanced CKD with high CV risk, low-dose rivaroxaban vs. placebo did not reduce CV events and increased major bleeding.
Where this comes from
- Record sourced from PubMed, PMID 42673594.
- Also identified by DOI 10.7326/ANNALS-26-03150-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text] Hematology: [Formula: see text].